GC Wealth Management RIA LLC Buys 7,611 Shares of Pfizer Inc. $PFE

GC Wealth Management RIA LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 46.4% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 24,012 shares of the biopharmaceutical company’s stock after purchasing an additional 7,611 shares during the period. GC Wealth Management RIA LLC’s holdings in Pfizer were worth $582,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Bessemer Group Inc. grew its holdings in shares of Pfizer by 11.1% during the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company’s stock valued at $3,358,000 after purchasing an additional 13,228 shares during the last quarter. Capital Advisors Inc. OK grew its holdings in Pfizer by 1.2% in the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock worth $35,817,000 after acquiring an additional 17,032 shares during the last quarter. CHURCHILL MANAGEMENT Corp bought a new stake in Pfizer in the 1st quarter worth $8,283,000. Westbourne Investments Inc. bought a new stake in Pfizer in the 1st quarter worth $2,411,000. Finally, Bourne Lent Asset Management Inc. grew its holdings in Pfizer by 90.8% in the 2nd quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock worth $927,000 after acquiring an additional 18,200 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on PFE. Bank of America raised their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday. Citigroup raised their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Finally, Morgan Stanley lifted their target price on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Pfizer currently has an average rating of “Hold” and an average target price of $28.12.

Pfizer Stock Up 6.8%

Shares of Pfizer stock opened at $25.46 on Wednesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The stock has a market capitalization of $144.75 billion, a PE ratio of 13.54, a price-to-earnings-growth ratio of 0.77 and a beta of 0.55. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The company has a 50-day simple moving average of $24.55 and a two-hundred day simple moving average of $24.11.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.